2024-12-04 REL RCSB RCSB RCSB 2023-07-13 2024-05-22 2024-05-22 2024-12-04 National Institutes of Health/Office of the Director OD021345 United States National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health & Human Development (NIH/NICHD) HD101596 United States National Institutes of Health/National Cancer Institute (NIH/NCI) CA260415 United States The Vallee Foundation Inc. United States Richard and Susan Smith Family Foundation United States National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) NS088566 United States The Pew Charitable Trusts United States Structure of AT118-L Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor and Losartan Skiba MA Kruse AC G protein-coupled receptor, nanobody, SIGNALING PROTEIN-IMMUNE SYSTEM complex Skiba MA Sterling SM Rawson S Zhang S Xu H Jiang H Nemeth GR Gilman MSA Hurley JD Shen P Staus DP Kim J McMahon C Lehtinen MK Rockman HA Barth P Wingler LM Kruse AC Antibodies expand the scope of angiotensin receptor pharmacology. Nat.Chem.Biol. US 20 1577 1585 2024 38744986 doi:10.1038/s41589-024-01620-6 1552-4469 EMD-41248 other EM volume 8th4 FULLOVERLAP AT118-L Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor BRIL Fusion protein, Anti-BRIL Fab, Anti-Fab Nanobody, and Losartan AT118-L Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor BRIL Fusion protein, Anti-BRIL Fab, Anti-Fab Nanobody, and Losartan 0 1 2 3 4 Homo sapiens Type-1 angiotensin II receptor Soluble cytochrome b562 complex Homo sapiens 0.049501059 1 Homo sapiens LEVO DYKDDDDKILNSSTEDGIKRIQDDCPKAGRHNYIFVMIPTLYSIIFVVGIFGNSLVVIVIYFYMKLKTVASVFLLNLALA DLCFLLTLPLWAVYTAMEYRWPFGNYLCKIASASVSFNLYASVFLLTCLSIDRYLAIVHPMKSRLRRTMLVAKVTCIIIW LLAGLASLPAIIHRNVFFIENTNITVCAFHYESQNSTLPIGLGLTKNILGFLFPFLIILTSYTLIWKALKKAYDLEDNWE TLNDNLKVIEKADNAAQVKDALTKMRAAALDAQKATPPKLEDKSPDSPEMKDFRHGFDILVGQIDDALKLANEGKVKEAQ AAAEQLKTTRNAYIQKYLERARSTLDKLNDDIFKIIMAIVLFFFFSWIPHQIFTFLDVLIQLGIIRDCRIADIVDTAMPI TICIAYFNNCLNPLFYGFLGKKFKRYFLQLLKY P30556 P0ABE7 P30556 BAG2 Anti-BRIL Fab Heavy Chain synthetic construct 0.024539313999999996 1 Homo sapiens LEVO EISEVQLVESGGGLVQPGGSLRLSCAASGFNVVDFSLHWVRQAPGKGLEWVAYISSSSGSTSYADSVKGRFTISADTSKN TAYLQMNSLRAEDTAVYYCARWGYWPGEPWWKAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD BAG2 Anti-BRIL Fab Light Chain synthetic construct 0.023541164 1 Homo sapiens LEVO DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQP EDFATYYCQQYLYYSLVTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AT118-L Nanobody synthetic construct 0.015345062999999999 1 Escherichia coli BL21(DE3) LEVO EVQLVESGGGLVQPGGSLRLSCAASGYIYSRYRMGWYRQAPGKGREFVAAISGGSSTNYADSVKGRFTISRDNSKNTVYL QMNSLRAEDTAVYYCAAYKIDSNPRVYWGQGTQVTVSSGKPIPNPLLGLDSTLEHHHHHH [2-butyl-5-chloranyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol 0.000422911 1 LSN singleParticle particle 7 7.4
20 mM HEPES, pH 7.4, 100 mM NaCl, 0.05% GDN, 0.005% CHS
 UltrAuFoil R1.2/1.3 GOLD 300 GLOW DISCHARGE ETHANE 100 293 FEI VITROBOT MARK IV FEI TITAN KRIOS FLOOD BEAM BRIGHT FIELD FIELD EMISSION GUN 300 0.8 1.8 FEI TITAN KRIOS AUTOGRID HOLDER SerialEM 4.0.5 GATAN K3 BIOQUANTUM (6k x 4k) 64.1 1 405950
Ab Initio Model
 C1 3.3 FSC 0.143 CUT-OFF cryoSPARC 3 238621 RANDOM ASSIGNMENT cryoSPARC 3 MAXIMUM LIKELIHOOD cryoSPARC 3 emd_41249.map.gz 1 IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) 352 352 352 0 0 0 352 352 352 292.16 292.16 292.16 90.0 90.0 90.0 X Y Z -1.17865 1.5787838 0.00023604 0.022130158 0.83 0.83 0.83 0.213 AUTHOR Locally Refined Sharpened Map of AT118-L, AT1R-BRIL and BAG2 Anti-BRIL Fab Variable Domains in Complex with Losartan emd_41249_additional_3.map.gz 1 IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) 352 352 352 0 0 0 352 352 352 292.16 292.16 292.16 90.0 90.0 90.0 X Y Z -1.1531684 1.6910146 0.00024237599 0.023158295 0.83 0.83 0.83 AUTHOR Global Sharpened Map of AT118-L, AT1R-BRIL,BAG2 Anti-BRIL Fab, and anti-Fab Nanobody in Complex with Losartan emd_41249_additional_2.map.gz 1 IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) 352 352 352 0 0 0 352 352 352 292.16 292.16 292.16 90.0 90.0 90.0 X Y Z -0.25940698 0.57861334 0.0005439425 0.02173331 0.83 0.83 0.83 AUTHOR Half Map A of Global Map of AT118-L, AT1R-BRIL,BAG2 Anti-BRIL Fab, and anti-Fab Nanobody in Complex with Losartan emd_41249_additional_1.map.gz 1 IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) 352 352 352 0 0 0 352 352 352 292.16 292.16 292.16 90.0 90.0 90.0 X Y Z -0.28030983 0.57829666 0.00054367346 0.02159534 0.83 0.83 0.83 AUTHOR Half Map B of Global Map of AT118-L, AT1R-BRIL,BAG2 Anti-BRIL Fab, and anti-Fab Nanobody in Complex with Losartan emd_41249_half_map_2.map.gz 1 IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) 352 352 352 0 0 0 352 352 352 292.16 292.16 292.16 90.0 90.0 90.0 X Y Z -0.49230218 0.66377074 0.00054468523 0.053303685 0.83 0.83 0.83 AUTHOR Half Map A of Locally Refined Sharpened Map of AT118-L, AT1R-BRIL and BAG2 Anti-BRIL Fab Variable Domains in Complex with Losartan emd_41249_half_map_1.map.gz 1 IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) 352 352 352 0 0 0 352 352 352 292.16 292.16 292.16 90.0 90.0 90.0 X Y Z -0.43138546 0.6632947 0.0005470836 0.05333475 0.83 0.83 0.83 AUTHOR Half Map B of Locally Refined Sharpened Map of AT118-L, AT1R-BRIL and BAG2 Anti-BRIL Fab Variable Domains in Complex with Losartan